How SPRAVATO® Works — Explained for Tyler, TX Patients

NMDA (N-methyl-D-aspartate) receptors are a type of glutamate receptor — ion channels that open in response to glutamate binding, allowing calcium and other ions to flow into the neuron. NMDA receptors play a central role in synaptic plasticity — the ability of synapses to strengthen or weaken over time in response to activity.

In treatment-resistant depression, there is evidence of disrupted NMDA receptor signaling and reduced synaptic plasticity in prefrontal cortical circuits that regulate mood, executive function, and stress response. Chronic stress — a key driver of depression — leads to dendritic retraction and synaptic loss in these circuits.

SPRAVATO® (esketamine) is a non-competitive NMDA receptor antagonist. By blocking NMDA receptors, esketamine interrupts a specific inhibitory signaling pathway (involving interneurons that suppress excitatory circuits) and allows glutamatergic excitatory signaling in prefrontal circuits to increase. This increase in excitatory signaling triggers downstream molecular cascades — including activation of the mTOR pathway and release of BDNF (brain-derived neurotrophic factor) — that promote the growth of new synaptic connections.

The clinical result of this molecular cascade is rapid synaptogenesis: the creation of new synaptic connections in the prefrontal cortex and related structures. This structural change may reverse or partially restore the dendritic and synaptic deficits associated with chronic depression.

Synaptogenesis — the formation of new synaptic connections — is believed to be central to SPRAVATO®'s antidepressant mechanism. This is what distinguishes esketamine's mechanism from traditional antidepressants at the structural level.

SSRIs increase serotonin availability in the synapse, which over time may produce some degree of synaptic remodeling — but this process is slow (weeks to months) and incomplete in many patients. SPRAVATO® triggers synaptogenesis more directly and more rapidly, through the glutamatergic and mTOR signaling cascades, producing structural changes in prefrontal circuits that can emerge within hours to days of a dose.

In animal models, a single dose of ketamine produced rapid increases in synaptic density in prefrontal areas that were deficient in stress-exposed animals — and this structural change corresponded with rapid behavioral improvement in depression-related tests. Human neuroimaging studies have shown similar changes in connectivity and activation patterns after esketamine treatment.

This is why SPRAVATO® can work faster than traditional antidepressants and why it can work for patients who have not responded to multiple SSRIs or SNRIs — it is not doing more of what failed, but doing something structurally different in the brain.

The faster onset of SPRAVATO® compared to traditional antidepressants — days versus weeks — follows directly from its mechanism of action.

SSRIs work by blocking serotonin reuptake transporters, which increases serotonin availability in the synapse. But the antidepressant effect of this increase is not immediate — it requires downstream receptor adaptation, including desensitization of autoreceptors that initially suppress serotonin neuron firing in response to increased synaptic serotonin. This autoreceptor desensitization process takes two to four weeks, which is why SSRIs take that long to produce their full antidepressant effect.

SPRAVATO® triggers synaptogenesis through a faster signaling pathway. The mTOR cascade and BDNF release that produce new synaptic connections occur within hours of a dose. The resulting structural changes in prefrontal circuits — new synaptic connections in areas depleted by chronic depression — can produce antidepressant effects that emerge on a timescale of hours to days rather than weeks.

This faster onset is one of SPRAVATO®'s most clinically significant attributes. For patients with long treatment histories who have been waiting for relief across multiple medication trials, the possibility of improvement within days of the first session is meaningful.

SPRAVATO® is administered as a nasal spray rather than as a pill, injection, or intravenous infusion. The nasal route is important for several reasons — pharmacological, practical, and regulatory.

Pharmacologically, intranasal delivery produces a rapid onset of effect that matches the fast-acting mechanism of esketamine. The nasal mucosa is highly vascular, and absorption through nasal tissue produces peak plasma concentrations faster than oral administration (which requires gastrointestinal absorption and first-pass hepatic metabolism). This makes intranasal delivery particularly appropriate for a medication whose clinical value partly lies in its speed of action.

Practically, intranasal delivery is easier to standardize across patients and clinic settings than IV infusion, which requires IV access and more intensive monitoring. The nasal device delivers a precise dose in a reproducible way.

Regulatory and safety: SPRAVATO®'s REMS program prohibits home use — regardless of the delivery route. The intranasal route was specifically selected by the manufacturer partly to make outpatient administration feasible, but the REMS monitoring requirement ensures that feasibility does not come at the expense of safety.

We accept Aetna, Ambetter, Blue Cross Blue Shield, Cigna/Evernorth, Medicare, Optum, UnitedHealthcare, and UMR.

Understanding how SPRAVATO® works helps you engage more actively and thoughtfully in your own treatment.

Expectations about onset: Because SPRAVATO® triggers synaptogenesis rather than gradual receptor adaptation, you may notice early signs of improvement — in mood, energy, or motivation — within the first few days rather than the first few weeks. This is not universal, and you should not interpret an absence of dramatic improvement in the first session as treatment failure. But you should pay attention to subtle changes in your daily function between sessions, because these may be early signals of a response.

Understanding the monitoring period: The acute dissociative effects of esketamine during monitoring are a product of its NMDA receptor activity — a direct pharmacological effect that is separate from the therapeutic antidepressant effect. You can experience significant dissociation during monitoring and still experience meaningful antidepressant effects in the days that follow. These are two different phenomena from the same mechanism.

Long-term thinking: The structural changes SPRAVATO® triggers — new synaptic connections — take time to consolidate and stabilize. The maintenance phase after induction is designed to support this consolidation, not just to sustain an acute pharmacological effect.

Call (430) 288-5800 or use the Schedule button to request a same-week consultation.

This page is educational and is not a substitute for personalized medical advice.